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Abstract 
 
Biomaterials used in regenerative medicine are often designed to act as 3-D porous templates 
(scaffolds) able to support and promote the growth and repair of natural tissues. Some types of 
glasses have a great potential as scaffold materials, as they can bond to host bone, stimulate bone 
cells towards osteogenesis and resorb at the same time as the bone is repaired. This review article 
highlights the evolution of glass-based scaffolds for bone tissue engineering; specifically, the 
features, limitations and advantages of the different types of glass-derived scaffolds proposed in the 
literature (macroporous glass-ceramic, sol-gel glass, composite, graded, hybrid and hierarchical 
implants) are critically examined, discussed and compared. Future directions for the research are 
also suggested, highlighting the promise of multifunctional systems combining bone regeneration 
and drug release abilities, the increasing role of microtomographical analysis for scaffolds 
investigation and the potential of stem cells incorporation into scaffolds. 
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INTRODUCTION 
 
Bone is a connective tissue exhibiting excellent properties of mechanical resistance especially due 
to its unique structure, in which cells are encased in a composite matrix essentially formed by 
collagen fibres and apatitic mineral phase. Bone is usually in need of regeneration or substitution 
due to tumours removal, trauma or age-related pathologies, such as osteoarthritis and osteoporosis. 
Two alternatives are possible for bone replacement: (i) transplantation or (ii) implantation.1 
Transplants can be made by using living or non-living tissues; at present, the commonly recognized 
“gold standard” in reconstructive bone surgery consists in the use of autografts, that involve 
harvesting the patient’s own tissue from a donor site and transplanting it to the damaged region. 
Autologous bone cause no immunological problems but can be collected in limited amount and its 
harvesting can induce death of healthy tissue at the donor site; in addition, problems related to 
second site morbidity, mismatching in mechanical properties with respect to host bone and tendency 
towards resorption may occur. A partial solution to these drawbacks is the use of allografts, i.e. the 
transplant of bone tissue from another living patient or from cadavers. However, allografts can 
cause disease transmission and carry the need of immunosuppressant drugs administration; 
furthermore, ethical and religious issues limit their use. 
Implantation involves the substitution of damaged tissues by using, in most cases, man-made 
biocompatible materials that are designed to act as scaffolds, i.e. porous templates with proper 3-D 
architecture able to promote tissue regeneration and/or remodelling. The general requirements 
featuring an ideal scaffold for bone tissue engineering have been outlined by several authors2-4; 
briefly, the scaffold is required to (i) act as a 3-D template for bone in-growth, (ii) produce non-
toxic degradation products, (iii) promote osteogenesis by inducing cells adhesion and proliferation, 
(iv) bond to the host bone creating a stable interface without the formation of scar/fibrous tissue, (v) 
possess mechanical properties matching those of natural bone, (vi) be tailored to match the shape 
and size of bone defects and (vii) be fabricated and sterilized according to international standards 
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for commercial production and clinical use. In addition, if the scaffold is temporary, it must resorb 
at the same time as the bone is repaired. 
Bioactive glasses, due to their versatile properties which can be properly designed depending on 
their composition, are very attractive materials for producing scaffolds devoted to bone 
regeneration.5 The first bioactive glass, belonging to the SiO2-Na2O-CaO-P2O5 system (Bioglass®), 
was synthesized by Hench and co-workers in the early 1970s6; since then, many other silicate, 
borate and phosphate glasses have been proposed by materials and medical researchers for bone 
tissue engineering applications. However, most of such glasses have been produced and tested in 
form of powders, particles, granulates or dense bulk of various shape and size, and only a limited 
group of them has been chosen to produce porous scaffolds. 
In this work, glass-based scaffolds will be classified in three main groups: (i) glass/glass-ceramic 
scaffolds with porosity at the macro-scale (the macropores size is over 50 nm, according to IUPAC 
classification), (ii) glass/polymer porous composites and (iii) glass/glass-ceramic scaffolds with 
hierarchical porosity in the macro- (> 50 nm) and meso-range (2-50 nm). The main features of the 
scaffolds belonging to these three classes and available in the literature will be concisely examined, 
discussed and critically compared also in the light of recent advances and findings. This review is 
especially dedicated to 3-D bone tissue engineering scaffolds; the use of glasses in soft-tissue 
engineering – e.g. for the fabrication of fibre-based constructs as nerve guides – will be mentioned 
only, when necessary, for purpose of completeness. To avoid any confusion on pore classification 
depending on their size, the authors strictly refers to IUPAC terminology. 
 
GLASSES FOR TISSUE ENGINEERING APPLICATIONS: SHORT OVERVIEW 
 
In the past, the research for biomaterials to be implanted for bone replacement especially focused on 
as inert as possible materials that did not interact with biological environment. However, since the 
last 1960s the attention moved towards materials exhibiting chemical and crystallographic 
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similarity to natural bone mineral, such as hydroxyapatite (HA), fluoroapatite and other calcium 
phosphates. Finally, in the last decades bioactive materials able to stimulate bone regeneration have 
mainly attracted researchers’ interest. A comprehensive picture about the ceramics used in medicine 
has been recently provided by Chevalier et al.7 As regards the biomaterials devoted to hard-tissue 
substitution, bioactivity has to be intended as the ability of the material to bond to bone creating a 
stable interface with patient’s host bone and, eventually, promoting natural bone regeneration.6 
Essentially, this ability is possible thanks to the formation on the biomaterial surface of a HA or 
apatite-like layer, mimicking the chemical and crystallographic features of bone mineral.8      
From a compositional viewpoint, bioactive glasses can be basically divided into three groups, 
depending on the main oxide present in the composition that generates the network (former oxide): 
(i) SiO2-based (silicate), (ii) B2O3-based (borate) and (iii) P2O5-based (phosphate) glasses. 
Specifically, the first group includes those glasses having a silica content below 60% mol., that was 
found to be the condition necessary, in melt-derived silicate glasses, for exerting bioactive 
responses.8 Borate glasses are, at present, less known and investigated with respect to the other two 
groups, in spite of their very interesting bioactive properties, even superior to those of silicate 
glasses.9,10 As far as the third group is concerned, it should be underlined that phosphate-based 
glasses may be both bioactive and bioresorbable11; however, most of studies has been focused 
especially on the resorption ability of phosphate glasses, and the literature about their bioactive 
behaviour is relatively scarce – also because their bioactivity has been found quite lower than that 
of silicate/borate glasses.11 
Above SiO2, B2O3 and P2O5, various amounts of other oxides can be added to impart peculiar 
properties to glass; for instance, CaO, K2O, Na2O and MgO are useful to adjust the rate of 
bioactivity process; ZnO, CuO, AgO and TiO2 allow the release of proper ions that can impart anti-
bacterial properties to the material; Al2O3 is helpful to strengthen the mechanical properties of 
glasses. It should be underlined that even a small variation in glass composition can deeply modify 
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the features of the material: in fact, different percentages of the same oxides will turn the glass 
properties towards bioinert, bioresorbable or bioactive. 
In addition, some ions can be incorporated in glass composition especially to give the biomaterial 
useful and appropriate properties in the context of bone tissue regeneration. For instance, zinc12,13 
and magnesium14 are known to exert a stimulatory effect on osteoblasts proliferation, differentiation 
and bone mineralization. Some research works carried out in the last two years have also 
demonstrated the great potential of strontium incorporation in the formulation of bioactive glasses 
as Sr2+ ions, when released from the glass, can reduce bone resorption, stimulate osteogenesis and 
accelerate bone healing processes.15-17 In such a context, some excellent works highlighting the 
great potential of the “genetic design” of bioactive glasses have been recently published.18,19  
Bioactive glasses are commonly produced by traditional melting-quenching routes or via sol-gel 
technique. Melt-derived glasses can be poured into moulds to produce rods, bars or as-cast 
components of various size and shape. The melt can also be quenched in cold water to obtain a 
“frit”, i.e. granules and pieces of different size that can be easily powdered. Finally, the glasses – 
especially the phosphate ones – can be also spun to fabricate glass fibres, that in the last decade 
have attracted increasing interest for application in soft-tissue engineering as guides for muscle or 
nerve repair. 
As above mentioned, the silica content should be less than 60% mol. to allow the glass to bond with 
bone, as shown by Hench.8 However, HA layer formation and bone bonding can be also achieved 
with glasses with up to 90% mol. silica if the glass is obtained by a sol-gel process.20 In general, 
sol-gel glasses were found to form the HA surface layer more rapidly than melt-derived glasses.21 
Glass can be converted by heating into a glass-crystals composite containing various kinds of 
crystalline phases with controlled sizes and content depending on the thermal treatment parameters. 
Generally, the resulting glass-ceramic exhibits superior mechanical properties with respect to the 
parent glass, specifically higher elastic modulus, hardness, failure strength and wear resistance.  
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FIRST-GENERATION GLASS-DERIVED SCAFFOLDS: GLASS/GLASS-CERAMIC 
MACROPOROUS STRUCTURES 
 
Various glasses of biomedical interest have been used as starting materials for fabricating porous 
scaffolds mimicking the 3-D trabecular architecture of natural spongy bone. Table I, compiled on 
the basis of the data available in the literature, reports an overview of the glasses specifically used 
for fabricating scaffolds; the features of the scaffolds produced from such materials, listed in Table 
II, will be described and critically examined in the following sections. It should be underlined that 
all known methods for producing inorganic glass-derived scaffolds (polymer/glass composite 
scaffolds are an apart category) require sintering treatments to ensure structural integrity; in most 
cases, the thermal treatment is carried out above the crystallization onset temperature and, therefore, 
the so-obtained sintered scaffolds are actually glass-ceramic due to crystals nucleation and growth. 
 
Bioglass®: a pillar of bone tissue engineering 
 
The invention of Bioglass®, synthesized for the first time about 40 years ago, led to a deep 
revolution in conceiving the role of biomaterials in human body: the perspective progressively 
moved from the seek for inert materials to be implanted towards the development of bioactive 
materials able to effectively promote natural tissue regeneration. Since the early 1970s, hundreds 
and hundreds of papers have been published about Bioglass® properties and applications. Just to 
cite a few examples, Peitl et al.22 and Clupper et al.23 examined in detail the effects of 
crystallization on the bioactivity of thermally treated glass-ceramic Bioglass® (GC-Bioglass®); 
Lefebvre et al.24 and Huang et al.25 investigated and modelled the sintering behaviour of Bioglass®; 
Xynos et al.26,27 as well as Hench28,29 studied the influence of the ions released by the glass on cells 
cycle and demonstrated that genetic design of bioactive glasses will be not only a dream in the next 
future. Recently, Hench published a very comprehensive review describing in detail the stages 
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involved in Bioglass® synthesis, biochemical/structural/biological testing and eventual 
commercialization.30 Bioglass® is in clinical use since 1985 in form of fine particulate for dental 
application (Perioglas, NovaBone, US); in addition, since the mid 1990s to present Bioglass® has 
been also commercialized worldwide in form of dense blocks and granulates of various size for 
bone defect filling and orthopaedic applications.  
The development of effective highly-porous Bioglass® scaffolds for clinical use is currently in 
progress: in fact, although Bioglass® was demonstrated to be an excellent bioactive material for 
promoting bone tissue regeneration, all porous bodies produced from it exhibited relevant 
brittleness and poor mechanical strength, as will be discussed later. 
 
Glass scaffold beginning: porous sol-gel glasses  
 
The first attempt to produce bioactive glass-derived scaffolds was carried out in 2002 by Sepulveda 
et al.31 by using the sol-gel foaming process. It should be noticed that bioactive glass foams based 
on 58S sol-gel glass, and not on the so-called Bioglass®, have been manufactured. Specifically, the 
synthesis method involved the sol foaming with the aid of a surfactant; on gelation, the spherical 
bubbles formed after sol shaking become permanent in the gel and led to a spongy structure similar 
to that of trabecular bone. Sol-gel glasses, as well as their derivative scaffolds, exhibit an excellent 
bioactive behaviour showing HA-forming kinetics faster that traditional melt-derived glasses.32 This 
is due to the high surface area available for ion-exchange phenomena with biological fluids: in fact, 
sol-gel foaming lead to scaffolds exhibiting a bimodal porous structure, constituted by large pores 
up to 500 µm connected by pores windows (10-100 µm) (Figure 1a) and a random-like mesoporous 
texture (10-50 nm). A very detailed and interesting study about the kinetics of apatite crystals 
formation on SiO2-CaO sol-gel glass scaffolds during immersion in SBF was recently carried out by 
Fitzgerald et al.33 These scaffolds can be considered the precursors of the third-generation scaffolds, 
in which, however, mesopores are arranged according to an ordered symmetry. We chose to present 
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sol-gel glass scaffolds here due to chronological reasons, as they were the first bioactive glass 
scaffolds to be fabricated. 
Many variables of sol-gel processing can be used to control the scaffold pores network structure, 
e.g. surfactant agent and glass composition.34,35 Jones et al.36 showed that by properly adjusting the 
sintering temperature of 70S30C glass foams the compressive strength of final scaffolds (Table II) 
can be increased from 0.3 up to 2.2 MPa; however, this range of values is dramatically lower than 
the strength of spongy bone (2-12 MPa) as well as the strength exhibited by other bone substitutes, 
such as clinically used HA (~6 MPa).8,37 The 3-D porous morphology of sol-gel foamed scaffolds 
has been recently investigated in detail by means of non-destructive X-ray computed 
microtomography (µCT)38 and was found very similar to the trabecular 3-D architecture of 
cancellous bone. However, it can not be ignored that these scaffolds are quite brittle and, therefore, 
are not suitable for bone replacement in dynamic high-load environments, such joint regions. 
Recently, Rainer et al.39 fabricated bioactive glass-ceramic scaffolds via in situ foaming starting 
from sol-gel 70S26C glass powders. This technique involved the dispersion of sol-gel glass 
powders in an appropriate liquid monomers batch; after complete polymerization, glass-loaded 
polyurethane foams were obtained, and a final thermal treatment allowed the polymer burning-out 
and the sintering of glass particles. The glass-loaded foams underwent severe shrinkage (>75%) 
during sintering and, therefore, were characterized by relatively low porosity (48 %vol.) in 
comparison with spongy bone. The scaffolds were bioactive and the proposed fabrication method is 
very interesting and versatile for producing patient-tailored grafts, but no indications about scaffold 
strength were presented.  
 
Bioglass®-derived scaffolds 
 
In 2006, Chen et al.40 prepared for the first time Bioglass®-derived scaffolds via sponge replication 
method (Figure 1b). A remarkable advantage of this method is the easiness to tailor the final 
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scaffold in terms of size and shape: in fact, the polymer template can be properly pre-formed and 
the scaffold geometry can be designed by taking in account the sample volumetric shrinkage due to 
sintering. The ability of such scaffolds to match bone defect dimensions is an important advantage 
for surgeons in the course of graft implantation procedures. However, the mechanical strength of 
the foam-like GC-Bioglass® scaffolds proposed by Chen et al.40 was one order of magnitude lower 
than that of cancellous bone (Table II); this can be attributed to Bioglass® sintering behaviour that 
led to hollow trabeculae in GC-Bioglass® final scaffolds (Figure 1c).25 It should be underlined that a 
so poor strength is a tremendous drawback that prejudices the clinical use of scaffolds, as 
difficulties related to samples manipulations by surgeons during surgical procedures, as well as 
problems of scaffold integrity in the early days after implantation, will occur. Some authors showed 
that the compressive strength of a scaffold can significantly increase in vivo due to tissue in-growth: 
in fact, cells adherent on scaffolds, newly formed tissue and the scaffold itself create a biocomposite 
in situ, thereby increasing the time-dependent scaffold strength.41  
More recently, Wu et al.42 prepared GC-Bioglass® scaffolds by using rice husk as pore former 
additive (Table II). The mechanical strength of such scaffolds is comparable to that of spongy bone 
and allows to avoid problems of scaffold integrity during handling and implantation, but their 
porosity content is below the lower threshold required for porous bone grafts (> 50%vol.). 
Therefore, although Bioglass® has demonstrated to be an excellent bioactive and biocompatible 
material and it has been in clinical use since 25 years, a lot of work is to be done to optimize the 
mechanical competency of porous scaffolds derived from it in such a way to make them actually 
suitable grafts for clinical applications. 
 
Scaffolds based on recently developed melt-derived silicate glasses 
 
The compositions of new silicate glasses proposed in the literature since the early 2000s and 
specifically used for producing bone tissue engineering scaffolds are listed Table I. It should be 
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underlined that glass compositions must be carefully selected in order to impart biocompatible and 
bioactive properties to final materials. Almost all methods used for scaffolding require a sintering 
treatment and, therefore, both the crystalline phases nucleated and grown during the thermal 
treatment and the residual amorphous phase should not induce toxic effect on cells or negatively 
affect the kinetics of bioactive process.    
The fabrication method deeply influences the structural properties of final scaffold, especially as far 
as pores features and mechanical strength are concerned (Table II). As already mentioned, the 
sponge replication, being easy, quick, versatile and inexpensive, is a very effective processing 
technique for making scaffolds. The morphology of foam-derived scaffolds43-45 is quite similar – in 
terms of pores content, size and 3-D architecture – to that of natural cancellous bone (Figure 1d); 
however, sponge replication usually led to scaffolds with low mechanical strength43-45 in 
comparison to cancellous bone (2-12 MPa)8,37 (Table II). Vitale-Brovarone et al.44 fabricated foam-
like GC-CEL2 scaffolds exhibiting a compressive strength up to 1 MPa and an excellent 
biocompatibility with osteoblasts; very recently, the same research group successfully optimized the 
process parameters to obtain scaffolds with even higher strength (5-6 MPa46) actually within the 
range assessed for spongy bone. This achievement can be mainly ascribable to the soundness of 
GC-CEL2 scaffolds trabeculae, that, differently from sponge-replicated GC-Bioglass® scaffolds40, 
did not present inward cavities (hollow struts). 
It is interesting to compare the results – in terms of scaffold structural and mechanical features – 
obtained by using sponge replication method or organic additive burning-out techniques to the same 
starting glass. Specifically, by having a look at the features of GC-CEL2 and GC-FaGC scaffolds 
reported in Table II, it is evident that scaffolds produced by using polyethylene (PE) burning-out 
method47,48 show mechanical strength higher than that the corresponding ones obtained via sponge 
replication43-46; however, it must be taken in account that this is possible at the expense of graft’s 
architectural similarity with natural bone. In fact, in such scaffolds the pores are separated by dense 
regions without the presence of the trabecular structure observed in the samples manufactured via 
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replication method43-46: therefore, the higher mechanical strength is negatively balanced by a 
morphology quite different than the one featuring cancellous bone and by a lower degree of pores 
interconnection. The absence of an actual trabecular morphology, mimicking that of cancellous 
bone, also characterized other two kinds of scaffolds derived from experimental glasses, i.e. GC-
SNCM49,50 and GC-SCK51 scaffolds. Scaffolds obtained by porogen additive burning-out, although 
having a low degree of pores interconnection, can be suitable for substituting load-bearing bone 
portions thanks to their high mechanical strength and good bioactivity. 
For purpose of completeness, a few remarks about the peculiar bioactive behaviour of SCK are 
presented. At present, SCK is the only Na2O-devoid silica-based bioactive glass used for making 
scaffolds, apart from sol-gel glasses (Table I). It is interesting to notice that the first stage of SCK 
bioactivity mechanism involves H+/K+ exchange phenomena, differently from Na2O-containing 
bioactive glasses. K+ has a quite large ionic radius (1.33 Å) in comparison with Na+ (0.95 Å); 
therefore, K+ release has a high disrupting effect on glass network enhancing SCK/GC-SCK 
specific surface area and reactivity. 51 In many glasses, both Na2O and K2O are present, as shown in 
Table II; in the case of GC-SCK scaffolds, the material reactivity is so high that cytotoxic effects on 
cells were detected due to an excessive pH increase (over 9).51  
As previously mentioned, the currently used processing techniques comprise a thermal treatment for 
glass particles sintering and, therefore, lead to glass-ceramic scaffolds. An interesting exception is 
represented by 3-D foam-like scaffolds based on the so-called 13-93 glass, that have been recently 
proposed by Fu et al.52: in fact, X-ray diffraction investigations demonstrated that the final scaffold 
remained amorphous. This can occur thanks to the peculiar sintering behaviour of 13-93 glass: in 
comparison with Bioglass®, for instance, 13-93 glass has more facile viscous flow behaviour, less 
tendency to crystallize and, therefore, a longer “sinterability window”.53 As reported in Table II, the 
porosity content and mechanical strength of 13-93 glass scaffolds are actually comparable to those 
of spongy bone; in addition, 13-93 glass has been approved for in vivo use in Europe. Therefore, 13-
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93 glass can be an effective resource for fabricating bioactive and mechanically competent scaffolds 
suitable for clinical applications. 
An open and challenging field of research concerns the chemo/physical treatment of glass/glass-
ceramic scaffolds for imparting them peculiar properties: for instance, Vitale-Brovarone et al.43 
recently proposed Ag-doped GC-FaGC scaffolds able to exert local antibacterial activity. 
 
Borate glass-derived scaffolds 
 
Bioactive glasses are, traditionally, silicate glasses in which silicon dioxide (SiO2) acts as glass 
network former. In the last 1990s, Brink et al.9 proposed for the first time boro-silicate glasses for 
biomedical applications, in which variable amounts of B2O3 were added to glasses composition to 
adjust their bioactive properties. 
Because of their lower chemical durability, borate glasses react faster and convert more completely 
to HA than Bioglass®, according to a mechanism recently proposed by Huang et al.10: in fact, 
partial or full replacement of SiO2 with B2O3 in glass composition results in a marked increase in 
the conversion of the glass to HA in aqueous phosphate solutions. The bioactivity of borate and 
boro-silicate glasses, as measured by its conversion rate to HA, can be varied over a wide range – 
from hours to months – depending on the glass composition. Thanks to their rapid and controllable 
conversion to HA, B2O3-containing bioactive glasses are attractive candidates for making scaffolds; 
in addition, from processing viewpoint, some borate/borosilicate glasses have been observed to 
undergo viscous flow sintering more readily than Bioglass®, thereby providing a more easily 
sinterable bioactive glass system for producing scaffolds.54 
At present, a relatively low number of studies on B2O3-containing glasses for biomedical 
applications has been carried out in the literature, essentially by three independent research groups 
affiliated to Missouri University of Science and Technology, East China University of Science and 
Technology and Tongji University of Shanghai. Scaffolds derived from borate glasses have been 
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proposed for the first time in 2005 and produced by soft pressing of glass powders (Table I) 
followed by sintering treatment.55,56 More recently, the interest of many researchers has been 
focused on 13-93B2 glass (Table I) as promising material for making foam-like scaffolds. Fu et 
al.57 used polymer foam replication to successfully produce 13-93B2 glass scaffolds with 
microstructure nearly identical to human trabecular bone. However, biocompatibility tests showed 
that borate ions, leached out of the glass, inhibited the proliferation of bone marrow stromal cells if 
the boron concentration was above a certain threshold value (0.65 mM).57 The toxic effect on cells 
could be alleviated by partial conversion of the borate-based glass to HA prior to cell culture, or by 
adopting dynamic cells culture conditions or else by carrying out proper dilutions of the phosphate 
solutions.58 The strength of 13-93B2 glass scaffolds was increased up to 10 MPa (pores content 
~70%vol.) by carefully optimizing the processing schedule adopted for scaffolds fabrication.59 The 
mechanism of conversion of 13-93B2 scaffolds in HA after soaking in dilute phosphate solutions 
has been recently investigated in detail by Liu et al.60 The peculiar bioactive properties of sponge-
derived borate glass scaffolds60, as well as their mechanical competence59 and structural similarity 
to trabecular bone, make them very promising candidates for clinical applications as bone grafts 
(Table II). However, as demonstrated by Liu et al.61, the progressive material degradation carries a 
significant drop of 13-93B2 scaffold strength (from 6.2 to 2.8 MPa after soaking for 15 days in 
phosphate solution). 
 
Phosphate glass-derived scaffolds 
 
In the last years, one of the major challenges of tissue engineering has concerned the design and 
development of materials able to safely dissolve once they have performed their function, thereby 
leaving the body to remodel the tissue to its natural form. For this purpose, since the last 1990s a 
novel group of glasses in which P2O5 acts as network former oxide has been proposed; the 
asymmetry of the [PO4] tetrahedron unit, which represents the structural unit of phosphate glasses, 
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is believed to be the origin of their low durability, together with the ease of P–O–P bonds 
hydration.62,63 Phosphate glasses can really have a great potential in regenerative medicine because 
their solubility is strongly dependent on their composition; therefore, their dissolution rate can be 
foreseen and tailored by adding metal oxides, such as TiO264-66, CuO67 and Fe2O368,69 to the glass 
composition. The two interdependent steps that take place during glass dissolution are hydration 
reaction, with a Na–H ion exchange, and phosphate network breakage in the hydrated layer due to 
the cleavage of P–O–P bonds.63 Due to their versatility, phosphate glasses have been widely studied 
as controlled release vehicles of antibacterial ions, such as silver, copper, zinc, gallium64-70; in 
addition, they were proposed as smart materials for soft-tissue engineering. In fact, phosphate glass 
nerve guides, like tubes or meshes, have been developed and tested in vivo71,72 with good results and 
3-D constructs for the repair of the muscular tissue have been also studied.73 In the field of hard-
tissue engineering, they have been also proposed in the context of bone tissue regenerative materials 
especially in form of bulk or powders, alone or with polymers in composite materials.11,64,65,74 It is 
interesting to mention that Abou Neel et al. very recently reported a detailed physical and structural 
characterization of a phosphate glass belonging to the Na2O-CaO-SrO-P2O5 system and suggested 
its use as a bone regenerative material75: strontium-containing glasses can be promising materials in 
bone tissue engineering as strontium is known to reduce bone resorption and accelerate bone 
healing processes.     
At present, very few phosphate glasses (Table I) have been specifically used for fabricating 3-D 
glass-derived scaffolds for bone grafting. In 2004, Navarro et al.76 successfully fabricated 3-D 
trabecular scaffolds from phosphate glass by H2O2 foaming. By varying the amount of incorporated 
H2O2 and the thermal treatment conditions, the total pores content and size, as well as the 
percentage of crystallinity could be modulated. More recently, Vitale-Brovarone et al. 
manufactured phosphate glass-ceramic scaffolds both via PE burning-out77 and sponge 
replication78,79 by using ICEL2 powders as glassy inorganic phase. ICEL2 composition (Table I) 
was designed by modifying that of silicate CEL2 glass: specifically, the molar amounts of SiO2 and 
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P2O5 in ICEL2 composition are inverted in comparison with CEL2 one. GC-ICEL2 scaffolds were 
found to be resorbable as, after soaking in different media (water, Tris-HCl, SBF), they underwent a 
process of continuous dissolution whose rate was both medium-dependent and time-dependent. In 
addition, GC-ICEL2 scaffolds were also bioactive, as a HA layer formed on their trabeculae after 
soaking in SBF. Bone marrow stromal cells cultured on the scaffolds maintained their metabolic 
activity, proliferation ability and seemed to be stimulated towards differentiation.79 Very recently, 
Cai et al.80 proposed the phosphate glass PG1 (Table I) as reinforcing phase in β-TCP-based 
scaffolds (percentage weight ratio: β-TCP : PG1 = 80 : 20). β-TCP/PG1 composite scaffolds 
exhibited enhanced mechanical properties (up to 6 MPa) with respect to pure β-TCP scaffolds (up 
to 2.3 MPa) as glass acted as viscous binder during sintering, thereby strengthening the final 
scaffold structure.  
 
SECOND-GENERATION SCAFFOLDS: GLASS/POLYMER POROUS COMPOSITES 
 
Conventional composite scaffolds 
 
Since the last 1990s, porous ceramic (glass)/polymer composites have been widely investigated 
with the purpose of imparting to the scaffolds peculiar properties, e.g. more finely controlled tissue 
interactions and drug release ability. The first attempts of fabricating porous composites involved 
the use of HA or amorphous calcium phosphate as inorganic phase and PLLA or PLGA as organic 
one.81-85 In the last decade, the researchers’ interest has progressively moved towards bioactive 
glass/polymer composites; the most attractive reason driving the development of these for bone 
tissue engineering composite scaffolds was the need for conferring bioactive behaviour to the 
polymer matrix, which can be achieved by glass inclusions or coatings. In fact, the degree of 
bioactivity can be foreseen and properly designed by adjusting the volume fraction, size, shape and 
arrangement of bioactive glass in the composite. However, the presence of bioactive glass in the 
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porous composite can alter the polymer degradation behaviour, thereby affecting the bioresorption 
kinetics of the scaffold.86,87 
Bioglass® has been the most commonly used glass phase used for making porous composite86-97, but 
also other silicate88, borate89 and phosphate glasses100-102 have been recently tested in combination 
with bioresorbable polymers. The porosity and strength of different glass/polymer composite 
scaffolds are compared in Table III, compiled from the data available in the literature. It is also 
worthy of mention here the work recently reported by Gentile et al.103 who prepared 
HA/CEL2/gelatin composite films; as the material exhibited good bioactive properties and 
promising mechanical features, the authors suggested its use for making porous composite 
scaffolds, and the related work is currently in progress.   
Many techniques have been developed to produce 3-D glass/polymer composite scaffolds with high 
pores interconnection; the most effective ones, i.e. thermally-induced phase separation86,87,94,95, 
microsphere sintering83,85,90 and coating methods88,89,98, have been extensively reviewed by Rezwan 
et al.104 and Mohamad Yunos et al.105 Solid free-form fabrication, although being a powerful tool to 
produce wholly polymeric scaffolds, at present has been only used for fabricating calcium 
phosphate/polymer porous composites.106,107 Very recently, Misra et al.97 used a unique 
combination of solvent casting/particulate leaching by employing sugar cubes as porogen additive 
for fabricating poly(3-hydroxybutyrate) (P3HB)/Bioglass® composite scaffolds.  
In general, the polymer makes the scaffold resorbable over time with degradation kinetics 
depending on the specific polymer used as matrix, whereas the glass inclusions or coating  impart 
bioactive properties to the structure and contribute to mechanically reinforce the polymer matrix. In 
2007, Bretcanu et al.96 proposed a different approach and fabricated porous composites by using a 
GC-Bioglass® scaffold manufactured via sponge replication as porous inorganic matrix40 and by 
coating it with P3HB. The polymer was specifically introduced to strengthen the GC-Bioglass® 
scaffold structure: in fact, P3HB layer acted as a glue thereby holding the inorganic particles 
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together when the scaffold struts start to fail. The compressive strength of such composite scaffolds 
(up to 1.5 MPa)96 was twice than that of bare GC-Bioglass® scaffolds (up to 0.4 MPa).40 
Glass/polymer composites have been mainly proposed for bone tissue engineering applications and, 
therefore, in vitro tested with some types of bone-related cells, e.g. bone marrow stromal cells108, 
human osteosarcoma cells (SAOS-2)90 and osteoblast-like cells line (MG-63).91,109 However, 
Verrier et al. also suggested the use of Bioglass®/PDLLA scaffolds for lung tissue engineering 
describing the results of an in vitro culture with human lung carcinoma cells (A549).93     
It can not be ignored that, as specifically remarked in some studies98,104, the mechanical properties 
(strength, stiffness) of today’s available polymer/glass composite scaffolds are inadequate if 
compared to the tissues they should temporarily replace. This drawback is particularly evident for 
implants designed for bone substitution, because polymer/glass porous composites are at least one 
order of magnitude weaker than natural cancellous bone, as reported in Table III. By comparing the 
mechanical properties of porous composites with those of purely polymeric scaffolds, a slight 
increase of strength and stiffness can be noticed, but a careful optimization of processing has to be 
done to reach values comparable to those exhibited by natural bone or its wholly glass-ceramic 
substitutes (Table II).  
 
Nanocomposite and hybrid scaffolds 
 
The poor or lacking bonding strength at the glass/polymer interface is, at least partially, responsible 
of the low increase of mechanical properties. In fact, it should be considered that glass phases are 
generally hydrophilic whereas polymers are hydrophobic; two possible solutions proposed by 
Rezwan et al.104 to overcome this problem could be the use of surfactants chemisorbed on glass 
particles surface prior to composite processing and/or the use of nano-sized glass particles to 
enhance the interfacial area and, therefore, the polymer/glass bonding strength. The latter approach 
has been followed very recently by Misra et al.109, who studied for the first time the effect of adding 
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bioactive glass nanoparticles (mean size ~29 nm) on the bioactivity, degradation and in vitro 
cytocompatibility of P3HB-based composites (Table III).  
In recent years, some researchers have gone beyond these even good suggestions and have made 
important attempts for developing nanoscale composite scaffolds. The challenge is very attractive, 
as the aim of creating nanocomposites is to have a nanoscale interaction between the bioactive 
inorganic phase and the organic one, so that the scaffold could degrade as one material rather than 
having mismatched degradation rates of a glass and polymer phase. As recently underlined by 
Jones110, this intimate interaction should allow cells to come into contact with both phases at one 
time, and the scaffold should degrade at a single rate. To the best of the authors’ knowledge, the 
nanoscale interaction of composite constituents has been always performed through the use of sol-
gel synthesis methods. The first approach, introduced by Pereira et al. in 2005111,112, involved the 
introduction of the polymer directly into the sol; specifically, poly(vinyl alcohol) (PVA) was chosen 
due to its biocompatibility and solubility in water. The so-obtained PVA/bioactive glass 
nanocomposite scaffolds exhibited unsatisfactory mechanical strength and degraded quite rapidly in 
SBF since PVA was not covalently bonded to the glass phase. The latter problem was overcome by 
functionalizing the chosen polymers, so that they can form covalent bond with the silica network, 
thereby creating a “hybrid” nanocomposite material characterized by an intimate interaction 
between glass and polymer at the atomic level. These hybrid materials are often termed “ormosils” 
(organically modified silicates), and have been recently reviewed by Arcos and Vallet-Regi.113 
Relatively few biocompatible polymers have been tested to obtain hybrids of interest in the 
biomedical field. Turning their attention to synthetic polymers, some researchers synthesized 
silica/poly(ε-caprolactone) (PCL) hybrid nanocomposites.114-118 The hydroxyl groups at both ends 
of the poly(ε-caprolactone diol) polymer chain were reacted with 3-isocyanatopropyl 
triethoxysilane, in order to obtain polymer chains bonded to triethoxysilyl groups. Eventually, this 
functionalized polymer was introduced into a sol to yield an interconnected PCL-silica network, 
thereby creating  an intimate interaction between the two phases. Up to now, such hybrids have 
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been tested only as bulk materials that showed good bioactivity and promising mechanical 
properties; in the next future, studies on the nanocomposite processed as a scaffold would be very 
important. Some researchers tested also natural polymers, such as chitosan and gelatine, to 
synthesize hybrid nanocomposites. In a work reported by Zhu et al.119, chitosan was reacted with 
methanesulphonic acid to form butyrylchitosan, able to react with acryloxypropyl trimethoxysilane 
to form a silanated butyrylchitosan, that was eventually introduced into a sol of hydrolysed TEOS to 
produce hybrid thin films. Ren et al.120-122 functionalized gelatin molecules with 3-
glycidoxypropyltrimethoxysilane before incorporation into the sol; hybrid scaffolds were then 
produced by soaking the gels in ammonia and freeze drying them. These hybrid scaffolds exhibited 
osteogenic properties with MC3T3-C cells, but no data about the mechanical properties have been 
reported yet. 
A final mention should be devoted to the so-called “star gels”, that  are a particular type of ormosils 
having an organic core surrounded by flexible arms which are terminated in alkoxysilane groups 
able to form a silica-like network during the sol-gel process.123 At present, only the star gel 
developed by Manzano et al. in form of monolith showed bioactive properties, as it induced the 
formation of an apatite-like phase after 7 days in SBF.124 The fracture toughness of star gels are, in 
general, higher than that of sol-gel glasses and comparable with natural bone; therefore, as 
suggested by some researchers, they are expected to exhibit good long-term fatigue behaviour.113,123  
 
THIRD-GENERATION-SCAFFOLDS: HIERARCHICALLY POROUS SYSTEMS 
 
Many systems and structures in nature are characterized by a complex gradient of organization at 
multi-scale levels. If we consider bone tissue, for instance, its architecture exhibits non-uniform 
porosity distribution. The hierarchical porous organization of bone is particularly evident at the 
macro-scale in the longitudinal cross-section of long bones, in which the bone at the ends 
(epiphyses) has the appearance of a sponge (cancellous or trabecular bone) whereas the bone in the 
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central part (diaphysis) is rather dense with low pores content (cortical bone). In addition, at a finer 
scale, other hierarchically structured pores systems, e.g. Haversian and Volkmann canals (diameter 
ranging within 100-250 µm), bone lacunae (5-10 µm) and canaliculi (1-5 µm), can be found.125 
As extensively reviewed by Miao et al.126, in recent years many researchers have tried to mimic 
nature by developing bioceramic bone tissue engineering scaffolds which exhibited gradients of 
porosity: in fact, heterogeneity of pores features can result in optimized structural, mechanical and 
biological properties in comparison to monomodal porous biomaterials. Very recently, scaffolds 
with multi-scale porosity from the meso- to the macro-range have been developed to impart to 
biomaterials advanced properties over the traditional, such as drug uptake/release abilities.127-130 It 
can not ignored that pore-graded and hierarchical multi-scale porous biomaterials are, in general, 
more difficult to fabricate than homogeneously porous materials. A short overview of such systems 
will be presented in the following sections. 
 
Scaffolds with gradient of porosity at the macro-scale 
 
As described in detail by Simske et al.131, four levels of pores size would characterize an ideal 
porous implant devoted to bone grafting. The first level (1-100 µm) is essential to impart 
biomimetic features to the biomaterial, as the surface roughness provided by small pores can 
enhance cells adhesion on the substrate. The second level (100-500 µm) can promote bone in-
growth, whereas larger pores (500-1000 µm), although contributing to decrease the mechanical 
strength, are useful to decrease the Young’s modulus of the implant in order to reduce stress-
shielding phenomena. Finally, pores over 1000 µm are useful for wires suture and fixation to 
patient’s host bone during surgical procedures. 
As recently reviewed by Miao et al.126, HA, β-TCP and other calcium-phosphate ceramics, as well 
as some of their composites with biocompatible polymers, have been widely adopted for making 
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graded scaffolds able to mimic the pore-graded structure of natural bone. Among bioactive glasses, 
however, at present only Bioglass®132 and CEL2133 have been proposed for the same purpose.  
Bretcanu et al.132 described quick and inexpensive methods for manufacturing 3-D highly porous (> 
80%vol.) foam-like GC-Bioglass® scaffolds (Table IV). The followed approach involved the use of 
pre-formed polyurethane sponges with tailored gradient of porosity as sacrificial templates for the 
replication technique. The porous polymer was pre-formed by compressing it in metal mould at low 
temperature (200 °C/1 h); by varying mould shape and size, PU templates with different porous 
features/gradients were successfully obtained. The pore-graded architecture is expected to reduce 
the dramatic brittleness of GC-Bioglass® structures with monomodal macroporosity40, but no 
evidences were reported yet in the literature.  
Vitale-Brovarone et al.133 used CEL2 particles to fabricate graded glass-ceramic scaffolds by means 
of  different processing methods, i.e. sponge replication, PE burning-out and enamelling, as well as 
various combinations of such techniques (Table IV). GC-CEL2 scaffolds able to mimic the porosity 
gradient of cancellous bone or to reproduce the trabecular/cortical bone system were obtained. In 
fact, as shown in Table IV it was possible to design the final scaffold – in terms of structural 
similarity to bone, pores features and mechanical strength – by varying the fabrication method, in 
order to fulfil specific criteria depending on the end use.    
 
Glass-derived scaffolds with hierarchical porosity at the macro- and meso-scale 
 
Mesoporous materials: short overview 
 
Mesostructured materials belong to the class of nanomaterials, whose properties can be tuned at the 
nanometrical scale. Specifically, according to IUPAC nomenclature, mesoporous materials are 
characterized by pores ranging within 2-50 nm. These materials are generally obtained by coupling 
a sol-gel method, that is very effective to prepare glasses and ceramics at room temperature, with a 
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supermolecular self-assembling process. This particular approach is possible by taking advantage of 
hydrophobic/hydrophilic features of some molecules, i.e. surfactants, to prepare supermolecular 
aggregates (micellae). The first successful synthesis of pure-silica mesostructured materials was 
performed in the early 1990s, when surfactants as structure-directing agents were used by Mobil Oil 
researchers.134 Since then, many classes of mesoporous materials with different pores features have 
been synthesized.  
As regards the biomedical field, mesoporous materials, being characterized by an ordered texture of 
nano-sized pores, can easily host drug molecules and, therefore, are good candidates for designing 
and producing systems for controlled drug delivery. In addition, the silanol groups located on the 
walls of silica mesoporous materials may be not only useful to functionalize the walls for enhancing 
the drug adsorption ability of materials, but can also react with biological fluids to produce HA or 
apatite-like nano-crystals.135 In vitro bioactivity studies, carried out by soaking SBA-15, MCM-41 
and MCM-48 in a simulated body fluid (SBF), revealed that an apatite-like layer was formed on the 
surface of SBA-15 and MCM-48 materials after 30 and 60 days of immersion, respectively.136 This 
behaviour is quite surprising as these mesophases, being constituted by pure silica, should not 
exhibit bioactive properties. In fact, according to Hench’s definition of bioactivity6,8, bioactive 
mechanisms can occur only if particular ion-exchange phenomena take place between material and 
surrounding fluids. On the other hand, it is obvious that mesoporous materials are non-traditional 
materials and, therefore, their mesoporous texture can impart them unexpected and fascinating 
properties. MCM-41 also exhibited a bioactive behaviour only if its walls were doped with 
phosphorus137 or by adding small quantities of bioactive glasses.138  
 
Mesoporous glasses 
 
In order to overcome the problems related to the uncertain bioactivity of pure-silica mesophases, 
several researchers have recently synthesized mesoporous bioactive glasses (MBGs)139-142, that 
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contain, above SiO2 as former oxide, also variable amounts of CaO and P2O5. The role played by 
the textural and structural properties of MBGs on their bioactive behaviour is extremely important 
and, therefore, it is necessary to shortly speculate about this point. Since the early 1970s, bioactive 
glasses are known to be able to chemically bond to living bone without formation of fibrous tissue 
around the implant due to the growth of a bone-like apatite layer on its surface.6 It was 
demonstrated that the HA formation on sol-gel glasses surface is related both to the structure and to 
the composition of the material, whereas melting-derived bioactive glasses show a direct 
dependence only from the composition.143 An increase of the pores volume and specific area (up to 
200 m2·g-1) in sol-gel glasses highly accelerates the deposition of HA, thus enhancing the bonding 
of the material to bone tissue.21,144 Ordered mesoporous silicas possess a very high surface area and 
an ordered system of generally open mesopores, but are not properly suitable as filling materials for 
bone repair because of their almost complete lack of bioactivity, as shown by Horcajada et al.138 
and very recently underlined by Mortera et al.144,145 Some authors reported a weak bioactive 
behaviour of SBA-15 and MCM-48, but only after relevant times of contact with biological fluids 
(> 30 days).136 On the contrary, MBGs belonging to the SiO2-CaO-P2O5 ternary system were found 
to exhibit a faster and higher bioactivity also in comparison with sol-gel glasses, thanks to their 
textural and structural properties (specific surface area up to 500 m2·g-1).139 Therefore, considering 
their superior bioactivity, MBGs may be a very promising material for bone tissue regeneration. 
 
Macro-/meso-structured scaffolds 
 
Sol-gel glass scaffolds31,34,39 can be considered the precursors of the hierarchically structured 
macro-/mesoporous glass scaffolds. However, although sol-gel glass scaffolds are characterized by 
both macro- and nano-pores, their mesoporous texture is not arranged in a well-defined symmetry, 
as it is intrinsically due to the sol-gel processing in itself.  
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In the last couple of years, some attempts for fabricating multi-scale glass-based scaffolds have 
been carried out by using properly mesostructrured material, in which nanopores size and 
arrangement can be carefully controlled and designed. The purpose of such scaffolds is twofold, as 
it combines the properties of traditional glass-derived scaffold, i.e. mechanical support in the defect 
zone, bioactivity, favoured osteointegration and bone tissue regeneration, with the unique features 
supplied by mesoporous materials, such as enhanced bioactivity and controlled drug 
adsorption/release ability for drug therapy in situ. Table V resumes the correlation between pores 
size and pores function in hierarchical porous scaffolds.  
The first prototype of such a system was developed by Cauda et al.127 and it involved the 
incorporation of SBA-15 mesoporous silicas inside a bioactive GC-SCK scaffold produced through 
PE burning-out method51, in order to obtain a composite scaffold able to promote the successful 
integration of the graft and the local drug (ibuprofen) delivery in the implant surroundings. This 
composite system showed a drawback related to the SBA-15 synthesis conditions (strongly acidic) 
which led to the GC-SCK scaffold degradation during the incorporation of the mesophase by 
dipping route. Afterwards, the study was extended to MCM-41 silica spheres, which posses 
narrower pores size in comparison with SBA-15, and the synthesis conditions were optimized in 
order to avoid the scaffold damage (mild pH ~9).128 Finally, a highly bioactive GC-FaGC scaffold 
was proposed as carrier for MCM-41 mesoporous spheres, that were found to play a key role in 
enhancing the drug adsorption ability of the whole composite system (Figures 2a and 2b).129 
Mortera et al. also showed that the size of MCM-41 spheres incorporated inside the scaffold may be 
carefully designed depending on synthesis condition to obtain mesophase spheres with narrow 
diameter distribution, without altering the drug uptake/release ability of the material.130   
Although the obtained results were promising and encouraging, however some remarks have to be 
taken in account: (i) the proposed systems (bioactive glass-ceramic scaffold + silica mesophase) are 
composite, i.e. constituted by two different materials that can present problems of interfacial 
bonding; (ii) the synthesis process of whole system is easy, inexpensive but requires long time; (iii) 
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although Izquierdo-Barba et al.136 reported the bioactivity of some pure-silica mesophases, this 
point is currently under debate in the literature and, specifically, several evidences seem to 
demonstrate the lacking of MCM-41 bioactivity.145,146  
An attractive solution to overcome the last problem (lacking of bioactivity in pure-silica 
mesophases) is, for instance, the manufacturing of monomaterial (non-composite) bioactive 
scaffolds with multiscale porosity by using MBGs. Recently, Yun et al.147 synthesized 
hierarchically porous 3-D MBG scaffolds with good in vitro bioactivity by using a combination of 
sol-gel, double polymers templating and rapid prototyping techniques. Li et al.148 reported the 
synthesis of multiscale porous MBG scaffolds by using the block copolymer EO20PO70EO20 (P123) 
and a PU macro-porous sponge as co-templates and demonstrated that a HA layer can form on 
scaffold surface after soaking in SBF for 4 h. Zhu et al.149 successfully prepared 3-D porous MBG 
scaffolds by a combination of PU sponge and P123 surfactant as co-templates and evaporation-
induced self-assembly (EISA) process (Figures 2c and 2d). Studies of biological compatibility 
showed that human bone-derived cells cultured on the scaffolds for 1, 3 and 7 days presented a 
good degree of attachment and spreading. In addition, hierarchical porous MBG scaffold exhibited 
a greatly enhanced bone-forming bioactivity as compared to traditional bioactive glass (BG) 
scaffold of same composition due to its high surface area and pore volume. Drug release studies by 
using gentamicin have been also performed.150 The drug uptake ability of MBG scaffolds was over 
twofold higher than that of BG scaffold; in addition, as far as drug delivery is concerned, during the 
whole release period in SBF gentamicin was delivered from the MBG scaffold at a much lower 
release rate as compared to that from BG scaffolds. 
At present, MBG scaffolds with multiscale porosity are at a preliminary stage of investigation, and 
a lot of research work has to be done in the future. For example, almost no indications about the 
mechanical strength of MBG scaffolds have been reported in the literature. In fact, only Wu et al.151 
very recently speculated about this point: firstly the authors tested as-such MBG scaffolds in 
compression (60 kPa), and afterwards they followed an approach similar to that proposed by 
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Bretcanu et al.96 to reinforce GC-Bioglass® scaffolds by using a polymeric coating. Specifically, 
Wu et al.151 soaked MBG scaffolds in silk solution and found that silk-induced modification 
improved the uniformity and continuity of scaffold pore network, maintained high porosity (~94 
%vol.) as well as large pore size (200-400 µm) and increased the mechanical strength up to 250 
kPa. It can not be ignored that the mechanical resistance of MBG-based scaffolds is over one order 
of magnitude lower than that of cancellous bone: this is a crucial drawback dramatically affecting 
any actual clinical applications, as the intrinsic mesoporous texture which features MBGs imparts 
high brittleness to scaffold structure, thereby causing problems related to sample manipulation and 
its safe implantation in patient’s bone.    
 
SUMMARY AND FUTURE CHALLENGES 
 
The classification of glass-based scaffolds in three generations adopted in the present work does not 
involve that the scaffolds belonging to a next generation are destined to replace those of a previous 
one. In fact, a lot of work is to be done in all three groups: the scaffolds belonging to different 
generations can exhibit peculiar properties which allow to overcome some problems or to 
emphasize specific abilities (e.g. bioactivity, drug incorporation), but it can not ignored that all of 
them present some limitations.  
By looking at the list of features that an ideal scaffold for bone tissue engineering should possess2-4, 
we have to admit that, at present, a porous structure able to fulfil all these criteria does not exist. 
Firstly, this occurs as it is very difficult to obtain glass-derived scaffolds exhibiting a satisfactory 
compromise between pores content and mechanical strength. For instance, although Bioglass® was 
invented four decades ago in the early 1970s6 and, at present, it is the best-known and 
commercialized bioactive glass worldwide 30, nonetheless no scaffolds effectively mimicking both 
the trabecular structure and the mechanical strength of spongy bone have been successfully 
synthesized from it up to now.40,42 A few consideration about this point, which has a crucial 
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importance, should be presented. Scaffold’s architectural design is still a great challenge because, 
from a structural viewpoint, two competing requirements are to be basically fulfilled: on one hand, 
the scaffold should exhibit a sufficient mechanical competence, i.e. strength and stiffness 
comparable to those of natural bone, but, on the other hand, once the scaffold is implanted in human 
body it should allow new bone in-growth within its own structure. This typically requires a pores 
content above 50 %vol. to allow blood vessels supply, cells migration and new tissue in-growth, as 
well as the presence of pores over 100 µm. These features compete with mechanical requirements, 
that are further discriminated if the scaffold is resorbable, as its integrity progressively decrease 
over time. This specific drawback seems to be particularly dramatic for glass/polymer composite 
scaffolds89-102, in which the structural and mechanical integrity is strongly affected by the 
progressive degradation of polymeric phase during the contact with biological fluids. On the other 
hand, porous composites carry unique properties for the incorporation and in situ release of 
biomolecules or organic moieties such as growing factors and antibiotics that can enhance, 
respectively, the new bone in-growth and the wound healing rate. However, it should be underlined 
that the assessment of long-term performances of such composite systems, with particular regard to 
their degradation over time, still remain a crucial work topic for foreseeing the actual scaffold 
behaviour in vivo; for this purpose, the effect of the incorporation of inorganic bioactive phases on 
scaffolds degradation and ion release kinetics should be still carefully studied, also by using 
properly developed predictive analytical models. 
Scaffold properties should be carefully designed on the basis of the final clinical use (e.g. load-
bearing needs, in situ drug release) and, in this sense, the choice of a proper method of fabrication 
plays a key role. There is a great variety of methods for scaffolds processing that lead to porous 
body with different structure, architecture, pores size and interconnection, and, at present, a “gold 
standard” method for scaffolding has not been defined yet. Sponge replication can be a good 
candidate in this sense due to its easiness, effectiveness, versatility and low cost; it was 
demonstrated that, by carefully setting the processing parameters46 and/or by producing graded 
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structure133, high-strength trabecular scaffolds can be successfully obtained. Solid freeform 
fabrication (SFF) methods could also be very suitable for manufacturing customized scaffolds. This 
class of techniques has been widely adopted to manufacture calcium phosphate152 and polymer 
implants2 with effective results, but up to now it has been very rarely used to process glass-
containing or glass-derived devices. To the best of the authors’ knowledge, this particular use of 
SFF has been reported only in two very recent works: Misra et al.97 used solvent casting/particulate 
leaching to produce P3HB/Bioglass® composite scaffolds, and Bergmann et al.153 adopted 3-D 
printing to manufacture β-TCP/Bioglass® composite implants. The major disadvantage of SFF 
techniques is, in general, the high production cost and, therefore, other less expensive processing 
methods have attracted the researchers’ interest. 
Finally, although there are procedures, guidelines and well-recognized standards for drugs and 
permanent implants (e.g. prostheses), there is not yet a regulatory system for devices, such as 
scaffolds, that will stimulate tissue growth and potentially resorb over time. Many issues still need 
to be defined more clearly, so that the researchers can have specific goals to aim for; hence, 
international standards for the production and clinical use of scaffolds are required to be developed. 
This point implies a deep and exhaustive knowledge of all the biological effects that can be 
potentially induced by scaffold materials in the human body. In fact, it was demonstrated in many 
research works that the ions released by bioactive glasses can exert a gene control regulation: for 
instance, silicon26-29, zinc12,13 and Mg14 ions were found to promote osteoblastic cells proliferation, 
differentiation and thus bone mineralization, and strontium ions are known to reduce bone 
resorption and to accelerate bone healing processes.15-19 In addition, it is possible to properly “dope” 
the scaffold in such a way that it can exert specific properties, such as antibacterial activity via ions 
release.43 Therefore, the genetic design of bioactive glasses and  their derivative scaffolds is a 
fascinating and attractive field of research able to open new perspectives towards a finely guided 
tissue regeneration. 
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Materials with hierarchical pores size distribution in the meso- (2-50 nm) and macro- (size > 50 
nm) range can offer interesting properties in comparison with the ones exhibiting only monomodal 
porosity. In general, a hierarchically structured porous system should comprise a macroporous 
structure serving as a support inside which a material having smaller pores can be incorporated.127-
130
 Ideally, the macroporous network aims to ensure the mechanical stability of the system, as well 
as good mass transport properties thanks to the high pores interconnection, whereas the mesophase 
can provide the functionality for a given applications, e.g. the encapsulation of biological or 
pharmaceutical agents. Glass-ceramic scaffolds are optimal candidates as substrates for the 
mesophases, as their relatively large geometric surface area (of the order of a few m2·g-1) and their 
highly interconnected 3-D pores network can allow the access of the mesophase also in the inner 
region of the structure.127-130 The purpose of such a system is twofold, as it combines the properties 
of the glass-derived scaffold, i.e. mechanical support in the defect zone, bioactivity, favoured 
osteointegration and bone tissue regeneration, with the unique features supplied by mesoporous 
materials, i.e. controlled drug adsorption and release allowing the possibility of drug therapy in situ. 
Mesoporous materials carry a great potential for bone tissue engineering, due not only to their 
unique textural properties, but also thanks to the remarkable versatility of their pores structure, 
symmetry and arrangement. The ability to introduce different organic species in mesoporous 
matrices could open new applications of these materials in tissue engineering. For example, 
mesoporous materials could act as scaffolds with embedded proteins, peptides or growth factors that 
would be released in a controlled way in the physiological fluids to promote cells proliferation and 
differentiation. The use of pure-silica mesoporous materials127-130 and MBGs147-151 in tissue 
engineering scaffolds manufacturing is still at a preliminary stage of research but the results 
achieved up to now are promising and challenging, too. In the authors’ opinion, efforts for 
fabricating MBG scaffolds with adequate mechanical strength, at least comparable to that of spongy 
bone, should be mandatory. 
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Controlled drug delivery from biomaterials and implants is a one of the most challenging issues not 
only of bone tissue engineering but also of the whole modern biomedical research. The release of 
therapeutic agents from scaffolds has been partially treated in the present work, especially as 
regards hierarchically porous glass systems; a comprehensive review about this topic was recently 
published by Mourino and Boccaccini.154 
As a final comment, it is necessary to underline that a great help for improving scaffold design and 
tailoring, as well as a more detailed assessment of scaffold features, can be provided by recent 
advanced techniques of non-destructive investigation. For example, the use of X-ray µCT can be a 
reliable tool for quantifying in detail the features of porous structures (struts thickness as well as 
pores size, shape, distribution and interconnectivity) (Figure 3a). A comprehensive picture about the 
great potential carried by non-destructive imaging techniques for characterizing porous structures 
was recently provided by Jones et al.155, who also underlined the need for appropriate algorithms 
for quantifying the µCT-derived parameters of interest. In addition, µCT data can be helpful to 
predict scaffold mechanical properties156 and permeability as a function of specific pores networks, 
that can be imparted to the scaffolds by means of different fabrication processes. However, µCT 
analysis can be applied only to structures with pores in the macro-range (size of few hundreds of 
nanometers or above), as at present resolutions below 500 nm are not yet possible.  
µCT can be also successfully used for the validation of mathematical models describing scaffold 
micromechanics156,157, that can really act as powerful tools for scaffold design towards an ideal 
synthetic bone graft. 
µCT, being a non-destructive technique of investigation, can also enable to analyze the scaffolds 
after in vitro and in vivo tests without damaging the samples. For instance, Renghini et al.158 used 
µCT to have quantitative data about scaffold in vitro bioactivity, by monitoring the kinetics of HA 
formation on scaffold pores walls (Figures 3b and 3c). The potential of µCT in characterizing 
tissue-engineered scaffolds and bone was recently highlighted by Belicchi et al.159, who showed 
that µCT can provide crux information about both mineral and organic phases (Figure 3d). In the 
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context of tissue engineering, µCT may be successfully applicable to monitor stem cells homing, 
after appropriate cells labelling with metal nanoparticles159, thereby providing a powerful tool of 
investigation with superior performances to other non-destructive techniques such as magnetic 
resonance imaging.  
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Figure legends 
 
FIGURE 1. Some examples of first-generation scaffolds: (a) typical sol-gel glass scaffold (adapted 
from [36] with permission); (b) GC-Bioglass® scaffold (adapted from [40] with permission); (c) 
hollow centre of a single strut in a GC-Bioglass® scaffold (adapted from [40] with permission); (d) 
GC-CEL2 scaffold (the SEM micrograph was acquired in such a way that the 3-D architecture and 
pores network interconnection are emphasized).   
 
FIGURE 2. Some examples of scaffolds with multi-scale porosity: (a) GC-FaGC/MCM-41 
composite scaffolds (adapted from [129] with permission); (b) MCM-41 spheres anchored on 
scaffold walls (adapted from [129] with permission); (c) SEM micrograph of a MBG scaffold 
(adapted from [149] with permission); (d) TEM image showing the nanotexture (mesoporous 
channels) of MBG scaffolds (adapted from [149] with permission). 
 
FIGURE 3. The potential of µCT in the characterization of bone tissue engineering scaffolds: (a) 
µCT image of a typical sol-gel glass scaffold (adapted from [110] with permission); (b) GC-CEL2 
scaffold after soaking for 28 days in SBF (green = scaffold material, blue = newly formed HA) 
(adapted from [158] with permission); (c) isolation of HA phase grown on GC-CEL2 scaffold walls 
after in vitro tests (adapted from [158] with permission); (d) scaffold after implant for 16 weeks in 
mice (yellow = scaffold material, green = newly formed bone, blue = soft tissues) (adapted from 
[159] with permission). 
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Tables 
 
TABLE I. Overview of the glasses adopted for making bone tissue engineering scaffolds. 
Compositio
n family a 
Glass denotation Scaffolds 
generation d 
Synthesis e Composition (%mol.) 
Silicate, 
silica-
phosphate 
Bioglass® b I, II M 46.1SiO2-26.9CaO-
24.4Na2O-2.6P2O5 
58S b I, III sg 60SiO2-36CaO-4P2O5 
70S30C b I, III sg 70SiO2-30CaO 
70S26C c I, III sg 70SiO2-26CaO-4P2O5 
SNCM b I M 50SiO2-16CaO-25Na2O-
9MgO 
SCK b I, III M 50SiO2-44CaO-6K2O 
FaGC b I, III M 50SiO2-18CaO-7Na2O-
6P2O5-7K2O-3MgO-9CaF2 
CEL2 b I, II M 45SiO2-26CaO-15Na2O-
3P2O5-4K2O-7MgO 
13-93 b I M 53SiO2-6Na2O-12K2O-
5MgO-20CaO-4P2O5 (%wt.) 
80S15C5P III ms 80SiO2-15CaO-5P2O5 
Borate, 
boro-
silicate, 
boro-silica-
phosphate 
Bor-0 c I M 20Na2O-20CaO,-60 B2O3 
13-93B2 b I M 6Na2O-8K2O-8MgO-22CaO-
36B2O3-18SiO2-2P2O5 
0106 b II M 50SiO2-22.6CaO-5.9Na2O-
4P2O5-12K2O-5.3MgO-
0.2B2O3 
Phosphate, 
phospho-
silicate 
TiGlass c I, II M 44.5P2O5-44.5CaO-6Na2O-
5TiO2 
ICEL2 b I M 45P2O5-26CaO-15Na2O-
3SiO2-4K2O-7MgO 
PG1 c I M 45P2O5-22CaO-25Na2O-
8MgO 
a
 Depending on the glass network former oxides.  
b
 Glass name found in the corresponding reference(s).  
c
 Glass name assigned in the present article if not present in the corresponding reference(s). 
d
 Glass use for making scaffolds of first (I), second (II) or third (III) generation, according to the 
classification followed in the present work. 
e
 M = melt-derived, sg = sol-gel, ms = meso-structured. 
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TABLE II. Features of first-generation glass/glass-ceramic scaffolds. 
Scaffold 
material a 
Fabrication method Mean porosity 
(%vol.) 
Mean strength 
(MPa)  
References c 
GC-Bioglass® Sponge replication  90.0 0.4  25,40 
Rice husk burning-
out 
43.5-47.2 b 5.4-7.2 b 42 
58S Sol-gel foaming - - 31,34,35 
70S30C Sol-gel foaming 82-88 b 0.3-2.2 b 36,38 
GC-70S26C In situ foaming 48 - 39 
GC-SCNM Starch (from corn, 
potato, rice) 
consolidation 
40.0 6.0 49,50 
GC-SCK PE burning-out 60-62 b 1.5-6.0 b 51 
GC-FaGC PE burning-out 23.5-50.0 b 20.0-55.0 b 47 
Sponge replication 75 2 43 
GC-CEL2 
 
PE burning-out 48 7 48 
Sponge replication 53.5-72.8 b 1.0-5.4 b 44-46 
13-93 Polymer foam 
replication 
85 11 52 
Bor-0 Soft pressing 40 - 55,56 
13-93B2 Polymer foam 
replication 
67.7-86.7 d 0.8-9.7 d 57-61 
GC-TiGlass H2O2 foaming 40-55 d - 76 
GC-ICEL2 PE burning-out 90 - 77 
Sponge replication 85 0.4 78,79 
Β-TCP/GC-
PG1 
Sponge replication 60-85 b 3.5-6 b 80 
a
 If present, the notation “GC-” followed by the name of the glass (Table 1) means that the material 
is a glass-ceramic derived from the parent glass by means of a thermal treatment above the 
crystallization temperature. 
b
 Different scaffolds batches were produced by varying the processing parameters in a controlled 
way (see the references for details). 
c
 Refer to the text for reference numbering. 
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TABLE III. 3-D glass/polymer conventional composite scaffolds. 
Materials Mean porosity (%vol.) Mean strength (MPa) References c 
Glass Polymer 
Bioglass® PLGA 43 0.42 a 89,90,95 
PLLA 77-80 1.5-3.9 b 92 
PDLLA 94 0.075 a 86,91,93,94 
P3HB 79-85 0.5-1.5 a 96,97,109 
CEL2 PU 90 0.1 b 98 
0106 PDLLA 68 0.6 a 99 
TiGlass PLA 95 0.020 a 100-102 
a
 Compressive strength. 
b
 Tensile strength. 
c
 Refer to the text for reference numbering. 
 
 
TABLE IV. Graded scaffolds fabricated by using glasses. 
Scaffold 
material 
Fabrication 
method 
Correspondence 
with natural bone 
structure 
Mean 
compressive 
strength (MPa) 
References a 
GC-Bioglass® Graded sponge 
replication 
Porosity gradient 
of natural 
cancellous bone 
- 
132 
GC-CEL2 Differential PE 
burning-out 
Porosity gradient 
of natural 
cancellous bone 
11.5 133 
Differential 
sponge 
replication 
1.9 
PE burning-out 
+ sponge 
replication 
6.3 
PE burning-out 
+ enamelling 
Cancellous/cortical 
bone system 
18.0 
Sponge 
replication + 
enamelling 
9.7 
a
 Refer to the text for reference numbering. 
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TABLE V. Relationship between pores size and function in hierarchically structured porous 
bone scaffolds for bone tissue engineering. 
IUPAC classification Sub-level Pores size Function 
Meso-scale Lower meso-scale 2-10 nm Drug uptake/release, 
bioactivity improvement 
Upper meso-scale 10-50 nm Bioactivity improvement 
Macro-scale Lower macro-scale 50 nm-100 µm Biomimetic properties, 
improved cells attachment 
Mid macro-scale 100-500 µm Bone in-growth, blood 
vessels access, cells 
colonization 
Upper macro-scale > 500 µm Bone in-growth, facilities 
for surgical fixation by 
surgical wires 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54 
 
 
Fig. 1 
 
 55 
 
Fig. 2 
 
 56 
 
Fig. 3 
 
 
 
 
